BG102880A - Cation virosomes as transfer systems for genetic materials - Google Patents

Cation virosomes as transfer systems for genetic materials

Info

Publication number
BG102880A
BG102880A BG102880A BG10288098A BG102880A BG 102880 A BG102880 A BG 102880A BG 102880 A BG102880 A BG 102880A BG 10288098 A BG10288098 A BG 10288098A BG 102880 A BG102880 A BG 102880A
Authority
BG
Bulgaria
Prior art keywords
virosomes
cation
preparation
transfer systems
genetic materials
Prior art date
Application number
BG102880A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ernst WAELTI
Reinhard Glueck
Peter Klein
Original Assignee
Nika Health Products Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Limited filed Critical Nika Health Products Limited
Publication of BG102880A publication Critical patent/BG102880A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
BG102880A 1996-05-08 1998-10-29 Cation virosomes as transfer systems for genetic materials BG102880A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08
PCT/EP1997/002268 WO1997041834A1 (en) 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material

Publications (1)

Publication Number Publication Date
BG102880A true BG102880A (en) 1999-05-31

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102880A BG102880A (en) 1996-05-08 1998-10-29 Cation virosomes as transfer systems for genetic materials

Country Status (28)

Country Link
US (1) US6210708B1 (en:Method)
EP (1) EP0902682A2 (en:Method)
JP (1) JP2000509404A (en:Method)
KR (1) KR100536983B1 (en:Method)
CN (1) CN1271992C (en:Method)
AR (1) AR007054A1 (en:Method)
AU (1) AU710170B2 (en:Method)
BG (1) BG102880A (en:Method)
BR (1) BR9709224A (en:Method)
CA (1) CA2253561A1 (en:Method)
CO (1) CO4600638A1 (en:Method)
CZ (1) CZ299809B6 (en:Method)
EA (1) EA003130B1 (en:Method)
GT (1) GT199700058A (en:Method)
HR (1) HRP970234B1 (en:Method)
HU (1) HUP9901790A3 (en:Method)
ID (1) ID17934A (en:Method)
NO (1) NO327726B1 (en:Method)
NZ (1) NZ332666A (en:Method)
OA (1) OA10916A (en:Method)
PA (1) PA8429201A1 (en:Method)
PE (1) PE65198A1 (en:Method)
PL (1) PL199201B1 (en:Method)
SK (1) SK152698A3 (en:Method)
SV (1) SV1997000032A (en:Method)
TN (1) TNSN97080A1 (en:Method)
WO (1) WO1997041834A1 (en:Method)
ZA (1) ZA973885B (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HUP0202809A2 (hu) * 1999-10-08 2002-12-28 Nika Health Products Limited Kationos DOSPER-viroszómák
ES2202218T3 (es) * 1999-12-17 2004-04-01 Schott Glas Capsula fulminante activable inductivamente para sistemas de retencion de pasajeros y circuito de prueba para esta capsula fulminante.
US20030139361A1 (en) * 2000-01-21 2003-07-24 Kazuhiro Yuda Drug for gene therapy
AU2002346084B2 (en) * 2001-07-23 2006-11-16 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
CN100488491C (zh) * 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
JP5606067B2 (ja) 2006-09-15 2014-10-15 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
EP2763696B1 (en) * 2011-10-07 2018-09-19 iSD Immunotech ApS Identification of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2018060212A1 (en) 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
AU655823B2 (en) * 1991-05-08 1995-01-12 Crucell Switzerland Ag Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
ATE223701T1 (de) * 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
WO1997041834A1 (en) 1997-11-13
GT199700058A (es) 1998-10-29
JP2000509404A (ja) 2000-07-25
US6210708B1 (en) 2001-04-03
CO4600638A1 (es) 1998-05-08
OA10916A (en) 2003-02-21
AU2776697A (en) 1997-11-26
KR20000010780A (ko) 2000-02-25
CZ299809B6 (cs) 2008-12-03
BR9709224A (pt) 1999-08-10
PA8429201A1 (es) 2000-05-24
ID17934A (id) 1998-02-12
SV1997000032A (es) 1998-03-27
HUP9901790A3 (en) 2010-11-29
EA003130B1 (ru) 2003-02-27
EA199800992A1 (ru) 1999-06-24
AU710170B2 (en) 1999-09-16
EP0902682A2 (en) 1999-03-24
CN1271992C (zh) 2006-08-30
NZ332666A (en) 2000-05-26
PE65198A1 (es) 1998-10-16
HUP9901790A2 (hu) 1999-08-30
HRP970234A2 (en) 1998-06-30
ZA973885B (en) 1998-11-06
KR100536983B1 (ko) 2006-06-29
NO985137D0 (no) 1998-11-04
AR007054A1 (es) 1999-10-13
PL199201B1 (pl) 2008-08-29
CN1225007A (zh) 1999-08-04
TNSN97080A1 (fr) 2005-03-15
CA2253561A1 (en) 1997-11-13
NO985137L (no) 1999-01-04
PL329853A1 (en) 1999-04-12
HRP970234B1 (en) 2002-04-30
CZ361498A3 (cs) 1999-03-17
NO327726B1 (no) 2009-09-14
SK152698A3 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
BG102880A (en) Cation virosomes as transfer systems for genetic materials
Seyedin et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone.
Butler The nature and significance of osteopontin
Kasugai et al. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter
Ihle et al. Phenotypic characteristics of cell lines requiring interleukin 3 for growth.
Brunner et al. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
Wang et al. Purification and characterization of other distinct bone-inducing factors.
Nilsen-Hamilton et al. Selective stimulation by mitogens of incorporation of 35S-methionine into a family of proteins released into the medium by 3T3 cells
CA2457632C (en) Identification and isolation of somatic stem cells and uses thereof
Guy et al. Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth.
Stadie et al. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP‐GalNAc: polypeptide N‐acetylgalactosaminyltransferase from milk or mammary carcinoma cells
ZA953629B (en) Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
AU2002355970A1 (en) Identification and isolation of somatic stem cells and uses thereof
AU3509995A (en) Overexpression of mammalian and viral proteins
KR20010030617A (ko) 유방 특이적으로 분비되는 유방암 단백질인 마마글로빈
Atherton et al. Dipeptidyl peptidase IV expression identifies a functional sub‐population of breast fibroblasts
Schwartz-Albiez et al. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells
WO2000043499A3 (en) ANTI-TRANSFORMING GROWTH FACTOR BETA (TGF-β) TREATED STEM CELL COMPOSITION AND METHOD
GB9722320D0 (en) Human cell cycle checkpoint proteins
Okamura et al. Localization of a maturation-dependent epididymal sperm surface antigen recognized by a monoclonal antibody raised against a 135-kilodalton protein in porcine epididymal fluid
Clark et al. Characterization of murine pregnancy decidua transforming growth factor b. I. Transforming growth factor b2-like molecules of unusual molecular size released in bioactive form
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
NO984491D0 (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
López-Moratalla et al. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins